Sichuan Newston Pharmaceutical

Sichuan Newston Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, specializing in the development of innovative small molecule drugs for oncology and metabolic diseases. The company's research strategy focuses on highly selective inhibitors for validated but challenging targets, aiming to provide more effective treatments for patients with limited options. Its lead program, NST-101, is a potent and selective FGFR4 inhibitor designed to treat FGF19-overexpressing hepatocellular carcinoma. Beyond oncology, Newston is advancing a pipeline of candidates targeting metabolic conditions such as nonalcoholic steatohepatitis (NASH). The company leverages its internal R&D capabilities to move programs from discovery through clinical proof-of-concept. Newston has established a presence in the Chengdu High-tech Zone, benefiting from the region's growing biotech ecosystem.